Study of CD9 Gene Regulation and Non-coding RNA in Childhood B-acute Lymphoblastic Leukemia Relapse

What this Trial Is About

B-acute lymphoblastic leukaemia B-ALL is the most common cancer affecting children, with about 20% of patients experiencing a relapse despite treatment advances. Researchers are studying the role of the protein CD9, which influences leukaemia cell movement and adhesion, to understand its connection to relapse. The study aims to explore how CD9 regulation, possibly controlled by non-coding RNAs, could serve as a marker for predicting relapses in children diagnosed with B-ALL. The study involves collecting bone and blood samples from newly diagnosed pediatric patients at three critical therapy points at diagnosis, after the first phase of treatment, and if relapse occurs. These samples will help researchers investigate the network of non-coding RNAs that may regulate CD9 expression. This research could identify new diagnostic or prognostic markers and potential therapeutic targets related to B-ALL relapse. Participants will undergo bone and blood sampling during their routine care at specified times. Researchers will analyze these samples to study the non-coding RNA network involved in CD9 regulation over a 5-year period. The study will monitor this network as a possible factor in disease progression and relapse prediction. The total participation includes these three sampling points aligned with treatment and relapse monitoring.

Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse